Home / Leaderboard / Redmile Group, LLC
Redmile Group, LLC
Jeremy Green · Hedge Fund · Long/Short Equity
Redmile Group, LLC is a San Francisco-based investment management firm founded in 2007 by Jeremy Green. The firm specializes in the healthcare sector, providing investment management and advisory services across both public and private markets. Its strategy encompasses both hedge fund and private equity approaches, with a primary focus on innovative companies in biotechnology, pharmaceuticals, and medical technology in the U.S. and internationally.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +55.9% |
| YTD return | +3.7% |
| Sharpe ratio | 3.39 |
| Win rate | 52% |
| AUM | $1.2B |
| Inception | Oct 1, 2025 |
| Updated | Oct 2, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.2B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | http://www.redmilegroup.com |
Current Holdings
Updated on Oct 2, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| KRYS | Krystal Biotech Inc | 17.5% | +40.6% |
| SRRK | Scholar Rock Holding Corp | 16.9% | +9.3% |
| IMNM | Immunome Inc | 8.6% | +28.7% |
| STOK | Stoke Therapeutics Inc | 8.0% | -4.7% |
| NRIX | Nurix Therapeutics Inc | 7.6% | +62.9% |
| ABSI | Absci Corp | 5.4% | +165.6% |
| AGMB | AgomAb Therapeutics NV American Depositary Shares | 4.6% | -36.6% |
| ETRA | Electra Therapeutics, Inc. Common stock | 4.5% | -10.4% |
| ANNX | Annexon Inc | 4.3% | -8.5% |
| NGNE | Neurogene Inc | 3.4% | +4.3% |
| STTK | Shattuck Labs Inc | 2.6% | +69.5% |
| RGNX | Regenxbio Inc | 2.6% | -23.1% |
| FATE | Fate Therapeutics Inc | 2.4% | +50.2% |
| BEAM | Beam Therapeutics Inc | 2.3% | -8.2% |
| SLN | Silence Therapeutics PLC | 2.0% | +34.2% |
| IDYA | Ideaya Biosciences Inc | 1.9% | +10.6% |
| ATTO | Attovia Therapeutics, Inc. | 1.4% | -18.7% |
| NUVB | Nuvation Bio Inc | 1.4% | +8.9% |
| COGT | Cogent Biosciences Inc | 1.3% | -3.4% |
| BMRN | Biomarin Pharmaceutical Inc | 1.3% | -13.9% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Sep 28, 2026 | SELL | KRYS | 16.4% → 17.5% |
| Sep 28, 2026 | SELL | SRRK | 17.1% → 16.9% |
| Sep 28, 2026 | SELL | SLDB | 1.5% → 0.0% |
| Sep 28, 2026 | SELL | RGNX | 2.8% → 2.6% |
| Sep 28, 2026 | BUY | AGMB | 5.9% → 4.6% |
Investment Style Analysis
Redmile Group, LLC is widely recognized for employing a Long/Short Equity strategy. As of Oct 2, 2026, the firm oversees approximately $1.2B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Sep 28, Redmile Group, LLC made a significant move by reducing the position in KRYS. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Redmile Group's investment philosophy focuses on identifying transformative trends and innovative firms within the healthcare industry to generate long-term value for investors. The firm's approach is rooted in rigorous fundamental research and deep sector expertise, employing a disciplined investment process to uncover early-stage and growth opportunities across healthcare subsectors, including life sciences and medical technology.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Redmile Group, LLC.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M -7.5%
- Glenview Capital Management, LLC — Larry Robbins · 3M +2.3%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +6.8%
- FengHe Fund Management Pte. Ltd. — John Wu · 3M -3.4%
Frequently asked questions
How is the simulated portfolio for Redmile Group, LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Redmile Group, LLC's largest holding?
As of the latest filing, Redmile Group, LLC's top position is Krystal Biotech Inc (KRYS), representing 17.5% of the portfolio. This reflects a high-conviction bet by the institution.
What is Redmile Group, LLC's historical performance and risk profile?
Our simulation indicates a total return of +55.9% with a win rate of 52%. Notably, the portfolio maintains a Sharpe Ratio of 3.39, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Redmile Group, LLC primarily invest in?
Redmile Group, LLC has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Redmile Group, LLC's portfolio concentrated or diversified?
Redmile Group, LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 43.0% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Redmile Group, LLC performed in 2026?
Our AI-simulated model portfolio for Redmile Group, LLC tracks a Year-to-Date (YTD) return of +3.7%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Jeremy Green manage Redmile Group, LLC directly?
Yes, Jeremy Green serves as the key portfolio manager for Redmile Group, LLC, overseeing the investment strategy and final capital allocation decisions.